BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 34358353)

  • 1. Systematic screening identifies a TEAD4-S100A13 axis modulating cisplatin sensitivity of oral squamous cell carcinoma cells.
    Li R; Li W; He F; Zhang M; Luo H; Tang H
    J Oral Pathol Med; 2021 Oct; 50(9):882-890. PubMed ID: 34358353
    [TBL] [Abstract][Full Text] [Related]  

  • 2. HMG20A was identified as a key enhancer driver associated with DNA damage repair in oral squamous cell carcinomas.
    Na L; Meijie Z; Wenjing Z; Bing Z; Yanhao D; Shanshan L; Yongle Q
    BMC Oral Health; 2022 Nov; 22(1):473. PubMed ID: 36335317
    [TBL] [Abstract][Full Text] [Related]  

  • 3. TEAD4-YAP interaction regulates tumoral growth by controlling cell-cycle arrest at the G1 phase.
    Takeuchi S; Kasamatsu A; Yamatoji M; Nakashima D; Endo-Sakamoto Y; Koide N; Takahara T; Shimizu T; Iyoda M; Ogawara K; Shiiba M; Tanzawa H; Uzawa K
    Biochem Biophys Res Commun; 2017 Apr; 486(2):385-390. PubMed ID: 28315328
    [TBL] [Abstract][Full Text] [Related]  

  • 4. LncRNA UCA1 promotes proliferation and cisplatin resistance of oral squamous cell carcinoma by sunppressing miR-184 expression.
    Fang Z; Zhao J; Xie W; Sun Q; Wang H; Qiao B
    Cancer Med; 2017 Dec; 6(12):2897-2908. PubMed ID: 29125238
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pluripotency transcription factor Nanog and its association with overall oral squamous cell carcinoma progression, cisplatin-resistance, invasion and stemness acquisition.
    Kashyap T; Nath N; Mishra P; Jha A; Nagini S; Mishra R
    Head Neck; 2020 Nov; 42(11):3282-3294. PubMed ID: 32710593
    [TBL] [Abstract][Full Text] [Related]  

  • 6. LncRNA LINC00152 promotes oral squamous cell carcinoma growth via enhancing Upstream Transcription Factor 1 mediated Mitochondrial Ribosomal Protein L52 transcription.
    Zou X; Hu X; He F; Zhang M; Kong X; Rui S; Liu Y; Wang L; Zheng X; Liu J; Li Z; Luo H
    J Oral Pathol Med; 2022 May; 51(5):454-463. PubMed ID: 34664331
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CMTM6 drives cisplatin resistance by regulating Wnt signaling through the ENO-1/AKT/GSK3β axis.
    Mohapatra P; Shriwas O; Mohanty S; Ghosh A; Smita S; Kaushik SR; Arya R; Rath R; Das Majumdar SK; Muduly DK; Raghav SK; Nanda RK; Dash R
    JCI Insight; 2021 Feb; 6(4):. PubMed ID: 33434185
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Up-regulation of TNF-alpha/NFkB/SIRT1 axis drives aggressiveness and cancer stem cells accumulation in chemoresistant oral squamous cell carcinoma.
    de Castro LR; de Oliveira LD; Milan TM; Eskenazi APE; Bighetti-Trevisan RL; de Almeida OGG; Amorim MLM; Squarize CH; Castilho RM; de Almeida LO
    J Cell Physiol; 2024 Feb; 239(2):e31164. PubMed ID: 38149816
    [TBL] [Abstract][Full Text] [Related]  

  • 9. miR-654-5p Targets GRAP to Promote Proliferation, Metastasis, and Chemoresistance of Oral Squamous Cell Carcinoma Through Ras/MAPK Signaling.
    Lu M; Wang C; Chen W; Mao C; Wang J
    DNA Cell Biol; 2018 Apr; 37(4):381-388. PubMed ID: 29364705
    [TBL] [Abstract][Full Text] [Related]  

  • 10. GAS5 alleviates cisplatin drug resistance in oral squamous cell carcinoma by sponging miR-196a.
    Yuan X; Jing Y; Guang M; Zhu J; Wang J; Wang Y; Zhang Y
    J Int Med Res; 2022 Oct; 50(10):3000605221132456. PubMed ID: 36310502
    [TBL] [Abstract][Full Text] [Related]  

  • 11. MicroRNA-485-5p targets keratin 17 to regulate oral cancer stemness and chemoresistance via the integrin/FAK/Src/ERK/β-catenin pathway.
    Jang TH; Huang WC; Tung SL; Lin SC; Chen PM; Cho CY; Yang YY; Yen TC; Lo GH; Chuang SE; Wang LH
    J Biomed Sci; 2022 Jun; 29(1):42. PubMed ID: 35706019
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Prognostic Model Based on Cisplatin-Resistance Related Genes in Oral Squamous Cell Carcinoma.
    Lu R; Yang Q; Liu S; Sun L
    Oral Health Prev Dent; 2024 Jan; 22(1):39-50. PubMed ID: 38223960
    [TBL] [Abstract][Full Text] [Related]  

  • 13. TEAD4 functions as a prognostic biomarker and triggers EMT via PI3K/AKT pathway in bladder cancer.
    Chi M; Liu J; Mei C; Shi Y; Liu N; Jiang X; Liu C; Xue N; Hong H; Xie J; Sun X; Yin B; Meng X; Wang B
    J Exp Clin Cancer Res; 2022 May; 41(1):175. PubMed ID: 35581606
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Circ-PKD2 promotes Atg13-mediated autophagy by inhibiting miR-646 to increase the sensitivity of cisplatin in oral squamous cell carcinomas.
    Gao L; Zhang Q; Li S; Zheng J; Ren W; Zhi K
    Cell Death Dis; 2022 Feb; 13(2):192. PubMed ID: 35220397
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cisplatin-induced programmed cell death ligand-2 expression is associated with metastasis ability in oral squamous cell carcinoma.
    Sudo S; Kajiya H; Okano S; Sasaki M; Katsumata Y; Ohno J; Ikebe T; Hiraki A; Okabe K
    Cancer Sci; 2020 Apr; 111(4):1113-1123. PubMed ID: 32012401
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The interaction of TEA domain transcription factor 4 (TEAD4) and Yes-associated protein 1 (YAP1) promoted the malignant process mediated by serum/glucocorticoid regulated kinase 1 (SGK1).
    He S; Zhang H; Xiao Z; Bhushan S; Gao K; Wang W
    Bioengineered; 2021 Dec; 12(1):601-614. PubMed ID: 33517828
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Downregulation of SELENBP1 enhances oral squamous cell carcinoma chemoresistance through KEAP1-NRF2 signaling.
    Zeng H; Zhao X; Tang C
    Cancer Chemother Pharmacol; 2021 Aug; 88(2):223-233. PubMed ID: 33907880
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bcl-xL expression and regulation in the progression, recurrence, and cisplatin resistance of oral cancer.
    Alam M; Mishra R
    Life Sci; 2021 Sep; 280():119705. PubMed ID: 34111459
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Exosomes containing miR-21 transfer the characteristic of cisplatin resistance by targeting PTEN and PDCD4 in oral squamous cell carcinoma.
    Liu T; Chen G; Sun D; Lei M; Li Y; Zhou C; Li X; Xue W; Wang H; Liu C; Xu J
    Acta Biochim Biophys Sin (Shanghai); 2017 Sep; 49(9):808-816. PubMed ID: 28910982
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of ERCC1 gene polymorphisms on response to cisplatin based therapy in oral squamous cell carcinoma (OSCC) patients.
    Avinash Tejasvi ML; Maragathavalli G; Putcha UK; Ramakrishna M; Vijayaraghavan R; Anulekha Avinash CK
    Indian J Pathol Microbiol; 2020; 63(4):538-543. PubMed ID: 33154302
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.